Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial

Figures & data

Table 1. Patient and tumor characteristics.

	Tamoxifen		Placebo
	N	%	N	%	p value
Total	164		153
Age					.19
≤40	26	16	13	9
41–50	48	29	50	33
51–60	56	34	50	33
61–70	34	21	40	26
Menopausal status					.72
Premenopausal	77	47	65	42
Perimenopausal	35	21	36	24
Postmenopausal	52	32	52	34
Estrogen receptor					.59
Positive	62	38	65	42
Negative	39	24	30	20
Unknown	63	38	58	38
Stage					.33
Stage 1	54	33	39	25
Stage 2	67	41	67	44
Stage 3	43	26	47	31

Figure 1. Panel A shows cumulative incidence for Breast Cancer Recurrence (BCR) of the 317 patients included in the intent to treat analysis who were randomly allocated to tamoxifen or placebo. Panel B shows the estimates in patients with confirmed ER positive or ER unknown tumors. Panel C shows the Kaplan–Meier estimates of overall survival of the 317 patients included in the intent to treat analysis who were randomly allocated to tamoxifen or placebo. The gray curves show the expected survival for the 317 patients, applying mortality figures of the general Danish population. Panel D shows the Kaplan–Meier estimates of overall survival in patients with confirmed ER positive or ER unknown tumors. Number of patients at risk are given below x-axes.

Figure 2. The forest plot illustrates exploratory subgroup analysis of overall survival according to menopausal status, ER status and Stage. Hazard ratios (HRs) refer to adjusted estimates obtained in the multivariate analysis of the intent-to-treat population. CI indicates 95% confidence interval. p-values are for test of heterogeneity of treatment effect.